BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 34588438)

  • 1. SPOP mutation induces DNA methylation via stabilizing GLP/G9a.
    Zhang J; Gao K; Xie H; Wang D; Zhang P; Wei T; Yan Y; Pan Y; Ye W; Chen H; Shi Q; Li Y; Zhao SM; Hou X; Weroha SJ; Wang Y; Zhang J; Karnes RJ; He HH; Wang L; Wang C; Huang H
    Nat Commun; 2021 Sep; 12(1):5716. PubMed ID: 34588438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
    Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
    Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
    Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
    Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance.
    Lee CJ; Lee H; Kim SR; Nam SB; Lee GE; Yang KE; Lee GJ; Chun SH; Kang HC; Lee JY; Lee HS; Cho SJ; Cho YY
    Cell Death Dis; 2024 Apr; 15(4):274. PubMed ID: 38632244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
    Steele N; Finn P; Brown R; Plumb JA
    Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells.
    Link PA; Gangisetty O; James SR; Woloszynska-Read A; Tachibana M; Shinkai Y; Karpf AR
    Mol Cancer Res; 2009 Jun; 7(6):851-62. PubMed ID: 19531572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G3BP1 inhibits Cul3
    Mukhopadhyay C; Yang C; Xu L; Liu D; Wang Y; Huang D; Deonarine LD; Cyrta J; Davicioni E; Sboner A; Robinson BD; Chinnaiyan AM; Rubin MA; Barbieri CE; Zhou P
    Nat Commun; 2021 Nov; 12(1):6662. PubMed ID: 34795264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
    Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
    Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF-β signaling regulates
    Jiao C; Meng T; Zhou C; Wang X; Wang P; Lu M; Tan X; Wei Q; Ge X; Jin J
    Aging (Albany NY); 2020 May; 12(9):7747-7760. PubMed ID: 32364525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes.
    Kang J; Shin SH; Yoon H; Huh J; Shin HW; Chun YS; Park JW
    Cancer Res; 2018 Mar; 78(5):1184-1199. PubMed ID: 29259012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
    Lee SH; Kim J; Kim WH; Lee YM
    Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
    Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
    Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
    García-Flores M; Casanova-Salas I; Rubio-Briones J; Calatrava A; Domínguez-Escrig J; Rubio L; Ramírez-Backhaus M; Fernández-Serra A; García-Casado Z; López-Guerrero JA
    Eur J Cancer; 2014 Nov; 50(17):2994-3002. PubMed ID: 25204806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
    Fan Y; Hou T; Dan W; Zhu Y; Liu B; Wei Y; Wang Z; Gao Y; Zeng J; Li L
    Cell Death Differ; 2022 Aug; 29(8):1611-1624. PubMed ID: 35194188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
    Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
    PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
    Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
    EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease.
    Garcia-Gomez A; Li T; de la Calle-Fabregat C; Rodríguez-Ubreva J; Ciudad L; Català-Moll F; Godoy-Tena G; Martín-Sánchez M; San-Segundo L; Muntión S; Morales X; Ortiz-de-Solórzano C; Oyarzabal J; San José-Enériz E; Esteller M; Agirre X; Prosper F; Garayoa M; Ballestar E
    Nat Commun; 2021 Jan; 12(1):421. PubMed ID: 33462210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
    Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
    Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
    Nikhil K; Haymour HS; Kamra M; Shah K
    Br J Cancer; 2021 Mar; 124(5):995-1008. PubMed ID: 33311589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers.
    Kim MS; Je EM; Oh JE; Yoo NJ; Lee SH
    APMIS; 2013 Jul; 121(7):626-33. PubMed ID: 23216165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.